relaxatory actions of the HDAC8 inhibitor compound 2 and the pan-HDAC inhibitor trichostatin A; 2) the coimmunoprecipitation of HDAC8 with several smooth muscle filamentous proteins including cortactin; and 3) the increased immunoprecipitation of acetylated forms of several smooth muscle filamentous proteins, including cortactin, following HDAC8 inhibition. Indeed, in appreciation of the burgeoning data suggestive of many nonnuclear proteins being targets of acetylation, in smooth muscle and other tissues, we referred to deacetylases as KDACs (for lysine deacetylase) rather than HDACs (1). This seems particularly pertinent for KDAC8.
In summary, we welcome the contributions of Li et al. (4) to the topic of smooth muscle protein modification by KDACs, yet suggest it should not go unnoticed that much of the merit of this article is to add information to an already existing body of work on this topic.
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